Markets

Amicus Therapeutics (FOLD) Soars: Stock Up 10% - Tale of the Tape

Amicus Therapeutics, Inc. ( FOLD ) was a big mover last session, as its shares rose roughly 10% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This continues the trend for the company since May 21, as the stock is now up nearly 19%.

In the last 30 days, the company witnessed two positive estimate revisions and the Zacks Consensus Estimate also moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.

Amicus Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Other better-ranked stocks in the medical sector include Gilead Sciences Inc. ( GILD ), ANI Pharmaceuticals, Inc. ( ANIP ) and Illumina Inc. ( ILMN ). All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

AMICUS THERAPT (FOLD): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD ANIP FOLD ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More